17
Participants
Start Date
August 6, 2021
Primary Completion Date
December 18, 2024
Study Completion Date
March 12, 2025
Efineptakin alfa
NT-I7 is administered via an intramuscular injection after CAR-T infusion on Day 21.
Tisagenlecleucel
Administered as standard of care as described in the package insert on Day 0.
Axicabtagene ciloleucel
Administered as standard of care as described in the package insert on Day 0.
Lisocabtagene Maraleucel
Administered as standard of care as described in the package insert on Day 0.
Duke Cancer Institute, Durham
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
Washington University in St. Louis, St Louis
City of Hope, Duarte
Lead Sponsor
NeoImmuneTech
INDUSTRY